A New Vaccine Delivery Vehicle and Adjuvant Candidate: Bordetella pertussis Inactivated Whole Cells Entrapped in Alginate Microspheres

Publisher： Bentham Science Publishers

E-ISSN： 1873-4286|23|18|2665-2672

ISSN： 1381-6128

Source： Current Pharmaceutical Design, Vol.23, Iss.18, 2017-07, pp. : 2665-2672

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Pertussis Toxin (PTX) and its Non-Toxic Derivatives as Vaccine Adjuvant and Microbicide

By  

Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry - Anti-Inflammatory and Anti-Allergy Agents), Vol. 10, Iss. 5, 1970-01 ,pp. : 358-367

Bentham Science Publishers

Access to resources Recommend Favorite

Characterisation of a novel airway late phase model in the sensitized guinea pig which uses silica and Bordetella pertussis as adjuvant for sensitization

By Heuer H.O.   Wenz B.   Jennewein H.-M.   Klaus Urich  

European Journal of Pharmacology, Vol. 317, Iss. 2, 1996-12 ,pp. : 361-368

Elsevier

Access to resources Recommend Favorite

Diphtheria-Tetanus-Acellular Pertussis Vaccine Adsorbed (Triacelluvax™; DTaP3-CB): A Review of its Use in the Prevention of Bordetella pertussis Infection

By Matheson A.J.   Goa K.L.  

Pediatric Drugs, Vol. 2, Iss. 2, 2000-03 ,pp. : 139-159

Adis International

Access to resources Recommend Favorite

Economic Evaluation of a New Acellular Vaccine for Pertussis in Canada

By Iskedjian M.   Einarson T.R.  

PharmacoEconomics, Vol. 19, Iss. 5, 2001-01 ,pp. : 551-563

Adis International

Access to resources Recommend Favorite

New acellular pertussis vaccine superior in Ontario, Canada

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 319, 2001-01 ,pp. : 8-8

Adis International

Access to resources Recommend Favorite